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Abstract: We have used Gene Ontology (GO) and pathway analyses to uncover the common functions associated to the 
genes overlapping Copy Number Variants (CNVs) in autistic patients. Our source of data were four published studies [1-
4]. We first applied a two-step enrichment strategy for autism-specific genes. We fished out from the four mentioned stud-
ies a list of 2928 genes overall overlapping 328 CNVs in patients and we first selected a sub-group of 2044 genes after 
excluding those ones that are also involved in CNVs reported in the Database of Genomic Variants (enrichment step 1). 
We then selected from the step 1-enriched list a sub-group of 514 genes each of which was found to be deleted or dupli-
cated in at least two patients (enrichment step 2). The number of statistically significant processes and pathways identified 
by the Database for Annotation, Visualization and Integrated Discovery and Ingenuity Pathways Analysis softwares with 
the step 2-enriched list was significantly higher compared to the step 1-enriched list. In addition, statistically significant 
GO terms, biofunctions and pathways related to nervous system development and function were exclusively identified by 
the step 2-enriched list of genes. Interestingly, 21 genes were associated to axon growth and pathfinding. The latter genes 
and other ones associated to nervous system in this study represent a new set of autism candidate genes deserving further 
investigation. In summary, our results suggest that the autism’s “connectivity genes” in some patients affect very early 
phases of neurodevelopment, i.e., earlier than synaptogenesis. 
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INTRODUCTION 
  Autism Spectrum Disorders (ASDs) are a group of neu-
rodevelopmental disorders that affects approximately 1 in 
150 individuals and are characterized by deficits in recipro-
cal social interaction, communication and patterns of repeti-
tive behaviours and restricted interests [5]. These “core defi-
cits” can be variable among patients as far their severity and 
time of onset is concerned. In addition, non-core symptoms 
(mental retardation, epilepsy, gastro-intestinal disturbances, 
macrocephaly etc.), are observed only in subgroups of pa-
tients. This remarkable phenotypic complexity probably un-
derlies multiple etiologies assumed to disrupt one or more 
phases of neurodevelopment. 
  A genetic etiology for ASD has been established and 
supported by several evidences including: (i) a higher con-
cordance rate in monozygotic compared to dizygotic twins 
[6, 7], (ii) detection of chromosomal aberrations in up to 3% 
- 7% of children with autism [8], (iii) linkage and linkage 
disequilibrium studies, and (iv) a higher chance of associa-
tion between autism with several monogenic disorders (all  
 
 
*Address correspondence to this author at the Dipartimento di Oncologia 
Sperimentale e Applicazioni Cliniche,
  Università degli Studi di Palermo, 
Via S. Lorenzo Colli, 312 Palermo, Italy; Tel: +39 91 6722852; Fax: +39 91 
6806420; E-mail: vromano@unipa.it 
reviewed in [5]). These studies have also led to the identifi-
cation of several loci implicated in ASDs etiology. 
  Despite these important progresses the genetic bases of 
Autism Spectrum Disorders remain poorly understood. A 
major factor responsible of this poor outcome relates to the 
complex genetic architecture of this disorder likely consist-
ing of a marked multilocus and multiallelic heterogeneity 
with both common and rare risk alleles occurring in the 
autistic population [9]. Additional levels of genetic complex-
ity would involve epigenetic and environmental factors, pos-
sibly interacting with risk alleles [10, 11]. 
  In recent years, genomics has added a new dimension to 
autism’s research. Taking advantage of microarray technol-
ogy, genomic analyses in autism have proceeded along three 
main directions: whole-genome expression profiling (e.g., 
[12]), whole-genome association studies (e.g., [13]) and the 
analysis of Copy Number Variants [1-3, 14-16]. These three 
experimental paradigms of genomic research have concep-
tual and technical differences, but on the same time they 
share the challenging task of extracting the autism-specific 
biological information from the large number of data typi-
cally generated in microarray analyses.  
  Copy Number Variants are operationally defined as sub-
microscopic insertions or deletions of DNA segments larger 
than 1 kb [17, 18]. These genomic mutations overlap thou-Functional Annotation of Genes Overlapping Copy Number Variants  Current Genomics, 2010, Vol. 11, No. 2    137 
sands of genes, many of which play pivotal roles in biologi-
cal pathways and may thus have profound effects on cell 
functions and human phenotype. In recent years there have 
been a growing number of studies demonstrating or suggest-
ing that CNVs make a substantial contribution to human 
disease [19, 20]. The predicted functional effects of Copy 
Number Variants would include gene expression changes 
through a variety of mechanisms such as dosage effects, dis-
ruption of gene coding sequences, alteration of splicing, 
change in the location or efficiency of important regulatory 
elements, loss of heterozygosity, imprinting (all reviewed in 
[19]).  
  Further insight on the potential biological implications of 
CNVs has been gained by studying the common functions 
shared by genes overlapping CNVs detected in patients af-
fected by various diseases using a variety of bioinformatic 
approaches. Relevant examples concerning diseases of the 
nervous system include amyotrophic lateral sclerosis (ALS), 
mental retardation (MR), schizophrenia (see Discussion for 
autism). For example, genes deleted specifically in patients 
with sporadic ALS encode proteins involved in oxidative 
phosphorylation, regulation of the actin cytoskeleton, and 
interactions between cytokines and their receptors [21]. 
Webber  et al. [22]  explored links between 148 MR–
associated CNVs and phenotypes from 5000 mouse gene 
knock-out experiments and found that these CNVs were sig-
nificantly enriched in those genes whose mouse orthologues, 
when disrupted, result in either abnormal axon or dopa-
minergic neuron morphologies. Genes disrupted by struc-
tural variants in patients with schizophrenia were signifi-
cantly overrepresented in pathways important for brain de-
velopment including neuregulin signalling, extracellular sig-
nal–regulated kinase/mitogen-activated protein kinase 
(ERK/MAPK) signalling, synaptic long-term potentiation, 
axonal guidance signalling, integrin signalling and glutamate 
receptor signalling [23]. 
  Compelling evidences that CNVs are implicated in 
autism’s etiology relate to the observation that the frequency 
of de novo (rare) CNVs is significantly higher in cases ver-
sus controls [1, 2, 14]. On the other hand, the relative poten-
tial pathogenic role of both rare de novo and more common 
inherited CNVs is still under debate and several hypotheses 
invoking variable penetrance and expressivity, possibly in-
fluenced by other factors such as a mutation in modifier 
genes (not involved in a CNV), epigenetic mechanisms 
and/or environment have been proposed [9, 24]. Moreover, it 
is reasonable to assume that, in principle, only a subset of the 
tens or hundreds of genes (if not just one) overlapping a 
“pathogenic” CNV would actually be linked to autism. 
  In this study, we have used Gene Ontology and Ingenuity 
pathway analyses to uncover the common functions associ-
ated to deleted or duplicated genes in autistic patients. Using 
data from four published studies our functional annotation 
analysis uncovered several biological processes related to 
nervous system development and function potentially related 
to autism’s pathogenesis.  
METHODS 
Data Sets 
  The four CNV datasets we have used in this study refer 
to 4 distinct populations of autistic patients previously ana-
lyzed by microarray technology [1-4] accounting for a total 
number of 268 patients (see Supplementary Table 1 for de-
tails). Genes overlapping each CNV in patients were identi-
fied and gene symbols were manually retrieved using the 
information contained in the NCBI Map Viewer Homo 
sapiens (human) genome view Build 35.1. The symbols re-
lated to genes overlapping each CNV in each patient were 
grouped to generate several lists of genes named by the ac-
ronym “CS” (CS = Combined Set; see Table 1). Each list 
was stored as a txt file and used for functional annotation 
analyses. An additional list of gene symbols corresponds to 
genes overlapping CNVs occurring in the general population 
that were downloaded from the Database of Genomic Vari-
ants (DGV: http://projects.tcag.ca/variation/). The version of 
DGV database (Build 35.1) used is updated on November 
10
th, 2008 and contains: (i) 31615 total entries (hg17), (ii) 
19792 CNVs, (iii) a total of 6225 CNV loci. All data han-
dling and storage were done using Excel (Microsoft).  
Cytoscape Networks  
  Bipartite networks were generated by Cytoscape software 
(http://www.cytoscape.org; version 2.6.2) with the aim of 
identifying the genes in CS1_All dataset that are shared by at 
least two patients. The input file contained (i) ID codes for 
the patients and (ii) the corresponding genes overlapping the 
CNVs in these patients. Two different types of nodes are 
displayed in the network (i.e., patient and gene). Nodes are 
connected only if a patient shares one or more genes with 
another or multiple patients. To increase the graphical reso-
lution of the networks’ regions with high connectivity the 
“spring” layout was used. 
Gene Ontology and Tissue Expression Analysis 
  The function of genes overlapping CNVs in patients was 
annotated and analyzed according to the three organizing 
principles of Gene Ontology (GO: http://www.geneontology. 
Table 1.  Description of the Gene Lists Used in this Study 
CS0  The complete list of genes overlapping all CNVs detected in autistic patients from the four studies (cited in Supplementary Table 1). 
The CS0 data set was not used for functional annotation analysis. 
CS1  The list of genes obtained after subtracting from the CS0 list the same genes also overlapping the CNVs reported in the Database of 
Genomic Variants (http://projects.tcag.ca/variation/). The three gene lists from the CS1 dataset generated and used for functional 
annotation analysis are: (i) CS1_All (all genes), (ii) CS1_Gain (the duplicated genes), (iii) CS1_Loss (the deleted genes). 
CS2  A sublist of the CS1 dataset referring only to the genes that are deleted or duplicated in at least two patients. The three gene lists 
from the CS2 dataset generated and used for functional annotation analysis are: (i) CS2_All (all genes), (ii) CS2_Gain (the  
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org: BP: Biological Process, MF: Molecular Function, CC: 
Cellular Component). The Database for Annotation, Visuali-
zation and Integrated Discovery (D.A.V.I.D.) 2008_version 
6
th (http://david.abcc.ncifcrf.gov) [25, 26] was used for GO 
analysis. For gene-enrichment analysis D.A.V.I.D. uses the 
“Ease score statistics”, an alternative name of Fisher Exact 
statistics, referring to the one-tail Fisher Exact test. P-values 
were corrected by the Benjamini correction which controls 
the False Discovery Rate (FDR). Lists not exceeding 2000 
genes were uploaded to D.A.V.I.D. Separated analyses were 
carried out for CS “All”, “Gain” and “Loss” gene lists. 
  The “Tissue expression” function of D.A.V.I.D. was used 
to regionally map in nervous tissue the expression of genes 
from CS2_All dataset. 
Ingenuity Pathway Analysis 
  Ingenuity Pathways Analysis (Ingenuity Systems®, 
www.ingenuity.com) was used to identify the most signifi-
cant biological functions, diseases and canonical pathways 
from the Ingenuity knowledge base associated to de-
leted/duplicated genes in autistic patients (CS1 and CS2 gene 
datasets). Separated IPA analyses were carried out for “All”, 
“Gain” and “Loss” gene lists. All IPA. analyses presented in 
this study were performed on august 2009. The significant 
over-represented functions, diseases and pathways were 
identified by the right-tailed Fisher's Exact Test using a 
threshold p-value < 0.05 after application of Benjamini-
Hochberg method of multiple testing correction. Finally, 
network analysis was performed by IPA using each gene list. 
Briefly, IPA overlays test genes onto a global molecular 
network developed from information contained in the Inge-
nuity knowledge base. Networks of uploaded genes are then 
algorithmically generated based on their connectivity. The 
score assigned to each network is the negative log of the p-
value, and is calculated by the right-tailed Fisher's Exact Test 
using the hypergeometric distribution. The threshold of p-
value used was < 0.05.  
RESULTS 
Enrichment for Autism-Specific Genes  
  The actual data we retrieved from the four published 
studies are reported in Supplementary Table 1. Specifically, 
the information on CNVs detected on autistic patients (size, 
start and end of each deletion or duplication), was used to 
manually retrieve altogether 2928 genes overlapping 328 
CNVs. In these CNVs the number of genes ranged from 1 to 
188. We named this gene dataset “CS0”. In order to generate 
a first set of autism-specific genes (enrichment step 1), we 
removed from “CS0” dataset, those genes which also overlap 
CNVs reported in Database of Genomic Variants. This new 
set, named “CS1_All”, contains 2044 genes overall dupli-
cated or deleted in 233 patients. A second set of autism-
specific genes (enrichment step 2) was obtained from 
CS1_All list by identifying those patients who share the 
same deleted or duplicated genes. To this end, we used Cy-
toscape to generate bipartite graphs for all genes from 
CS1_All dataset and related patients (see networks in Sup-
plementary Fig. 1). Thus, we overall identified 514 deleted 
or duplicated genes in 113 patients (the CS2_All gene list). 
The number of patients sharing at least one duplicated or 
deleted gene ranged from 2 to 10.  
Functional Annotation of Genes Overlapping CNVs  
  Gene Ontology analysis was carried out by the 
D.A.V.I.D. software with the aim of uncovering common 
functions associated to deleted or duplicated genes in autistic 
patients. The list of statistically significant (Benjamini cor-
rected p-values < 0.05) GO terms obtained for each of the 
CS1 and CS2 gene lists is reported in Supplementary Table 
2. An inspection of this Table revealed two important fea-
tures. First, a marked increase in number of GO terms ob-
tained with CS2 gene lists compared to CS1 gene lists. Of 
the 90 statistically significant GO terms (all Benjamini cor-
rected p values < 0.05) overall identified by D.A.V.I.D. with 
the 12 “CS1” and “CS2”gene lists, the highest number of 
GO terms (65 or 40 %) were detected only when the CS2 
gene lists were used (see Table 2). Table 2 clearly shows the 
strong effect generated by the two step enrichment strategy 
we have applied, i.e., the very low number of GO terms 
mapped by CS1 gene lists compared to CS2 gene lists. Con-
sistent with the latter results, no statistically significant GO 
terms were obtained with CS0_Loss and CS0_Gain gene 
lists (containing the DGV genes). CS0_All could not be 
tested because it largely exceeded the maximum (i.e., 2000) 
number of genes that can be analyzed by D.A.V.I.D. We 
have also performed GO analysis on the excluded genes only 
(each All, Gain, Loss list was analyzed separately) and also 
in this case no statistically significant GO terms were ob-
tained.  
Table 2.  Number of Genes in Each Dataset and Correspond-
ing Number of Detected GO Terms 
Dataset*  # Genes  # GO Terms** 
CS1_ All  2044  23 (1%) 
CS1_Loss 1074  32  (3%) 
CS1_Gain 1158  7  (<1%) 
CS2_All 514  65  (13%)   
CS2_Loss 152  60  (40%) 
CS2_Gain 254  2  (1%) 
*See Table 1 for explanation of acronyms referring to data sets used. 
**All GO terms are statistically significant (P-value corrected by the Benjamini 
method  < 0.05). 
 
  Second, nervous system development and function re-
lated genes were overrepresented in CS2 lists and particu-
larly in the list of deleted genes (CS2_Loss). Totally, 20 
genes from CS2 dataset were associated by D.A.V.I.D. to 
several nervous system-related GO terms. All 20 genes are 
associated to “nervous system development” GO term (see 
Table 3). These 20 genes overlap 10 CNVs on 7 chromo-
somes, and they are deleted or duplicated in at least two 
autistic patients because belonging to CS2 list. 
  I.P.A. software was used to identify functions, diseases 
and canonical pathways associated to duplicated and deleted 
genes from autism-specific CS1 and CS2 gene lists, respec-Functional Annotation of Genes Overlapping Copy Number Variants  Current Genomics, 2010, Vol. 11, No. 2    139 
Table 3.  Genes in CNVs of Autistic Patients Annotated to Nervous System Development, Functions and Diseases 
GO Terms (D.A.V.I.D.)  Genes* 
GO:0048699-generation of neurons  SPON2, ASZ1, WNT2, FARP2, SEMA5A, LOC440258, CAV2, NDN, PTPRZ1, SEMA3A, CHAT, 
CTTNBP2, CFTR  
GO:0001764-neuron migration  ASZ1, WNT2, CAV2, NDN, CTTNBP2, CFTR,  
GO:0007399-nervous system development  SPON2, SEMA3D, ASZ1, HES6, WNT2, FARP2, C4orf6, LOC440258, SEMA5A, CAV2, NDN, 
PTPRZ1, SEMA3A, DGCR14, FOXP2, CHAT, MSX1, CTTNBP2, CRMP1, CFTR  
GO:0022008-neurogenesis  SPON2, ASZ1, WNT2, FARP2, SEMA5A, LOC440258, CAV2, NDN, PTPRZ1, SEMA3A, CHAT, 
CTTNBP2, CFTR  
GO:0019905-syntaxin binding  ASZ1, WNT2, CAV2, CTTNBP2, CFTR  
I.PA. Functional Annotations 
contact repulsion of axons  SEMA3A, SEMA3D 
circadian rhythm of mice  CADPS2, PER2 
collapse of growth cone  SEMA3A, SEMA3D, SEMA5A 
chemotaxis of central nervous system cells  CAV1, SEMA3A 
chemorepulsion of sympathetic neuron  SEMA3A 
development of accessory nerve  SEMA3D 
development of facial nerve  SEMA3D 
development of glossopharyngeal nerve  SEMA3D 
development of vagus nerve  SEMA3D 
developmental verbal dyspraxia  FOXP2 
familial advanced sleep phase syndrome  PER2 
growth of retinal axons  SEMA5A 
guidance of olfactory glomeruli  SEMA3A 
innervation of first molar  SEMA3A 
morphogenesis of sympathetic trunk  SEMA3A 
pathfinding of retinal axons  SEMA5A 
quantity of olfactory glomeruli  SEMA3A 
Parkinson's Signaling  SEPT5, CASP3, GPR37, MAPK8, MAPK12, MAPK11 
Axonal guidance signalling**   ADAM10, BMP15, CRKL, EPHA7, FZD6, MAPK12, MLC1, OPN1SW, PDGFA, PIK3C3, PLXNB2, 
PRKAR1B, RAC3, SEMA3A; SEMA3D, SEMA5A, SEMA7A, SMO, WASL, WNT16, WNT2 
*Gene symbols in bold characters: duplicated genes, in plain text: deleted genes. 
**This is the only case where the multiple testing correction was not applied (see text for further explanation). 
tively (see Supplementary Table 3). In Supplementary Table 
3  only functions and diseases surviving the Benjamini-
Hochberg multiple testing correction have been reported. 
Consistent with the results obtained with D.A.V.I.D., CS2 
datasets could map many more functions than CS1 datasets. 
In addition, with only one exception (the “Parkinson’s sig-
nalling” canonical pathway, obtained with CS1_All gene 
lists) all other functions, diseases and canonical pathways 
related to nervous system were exclusively mapped by CS2 
gene lists.  
 In  Table  3 we report all nervous system-related GO 
terms, functions, canonical pathways and diseases identified 
by the D.A.V.I.D. and I.P.A. softwares respectively with 
their associated genes. 
  The “Network” function of I.P.A. was used to investigate 
known protein–protein and gene–gene interactions possibly 
existing among genes overlapping CNVs in autistic patients. 
Several networks with highly significant scores were ob-
tained for each of the three CS2 gene lists (“all”, “gain”, 
“loss”) (not shown). One of the top-scoring networks ob-
tained with CS2_All gene list is shown in Fig. (1). 
Genes Related to Axon Pathfinding  
  As it can be seen in Table 3, among the various I.P.A. 
functions, there are several ones involved in processes re-
lated to axon pathfinding. From canonical pathway analysis 
performed with IPA using CS2_Loss list without applying 
the multiple testing correction, “axonal guidance signalling” 
also emerged as the most significant pathway (p = 0.00531 140    Current Genomics, 2010, Vol. 11, No. 2  Sbacchi et al. 
using the right-tailed Fisher's Exact Test) with 6 associated 
genes from the latter list. Based on these observations we 
then screened the longer CS1_All gene list to look for addi-
tional genes associated to “axonal guidance signalling” Ca-
nonical Pathway. This search led to identify additional 15 
(21 in total) genes related to this pathway (also reported in 
Table 3). The total number of patients bearing a deletion or a 
duplication involving one or more of these 21 genes is 23. 
Since the genes of the CS1_All list refer to 233 patients (see 
above) we would expect 10% of autistic patients (23/233) 
bearing a defect in this pathway. The position, role and inter-
actions of proteins encoded by these genes in the “axonal 
guidance signalling” pathway, drawn using “Path designer” 
graphical tool of I.P.A. software, are shown in Supplemen-
tary Fig. (2). 
In Silico Tissue Expression Analysis 
  Using “Tissue expression” function of D.A.V.I.D. we 
have also mapped the regional expression of CS2_All genes 
within nervous system. On a total of 514 D.A.V.I.D. could 
only annotate 221 genes whose 139 (see Supplementary Ta-
ble 4) were expressed in nervous system and many of them 
appear to be expressed in several brain regions that have 
been shown to be altered in autism such as cerebral cortex, 
cerebellum, amygdala.  
DISCUSSION 
  In this study we have attempted a reconstruction of mo-
lecular and cellular mechanisms potentially involved in 
autism’s etiology by functionally annotating genes overlap-
ping CNVs detected in patients. The source of CNVs data 
were four published CGH-microarray studies [1-4] alto-
gether carried out on a large autistic population. Our meta-
analysis was based on three assumptions: (i) the number of 
autism susceptibility genes overlapping CNVs detected on a 
single patient may be insufficient to recover significant in-
formation in functional annotation analyses, (ii) only a sub-
set of all genes overlapping a “pathogenic” or “potentially 
pathogenic” CNV would be actually linked to autism, (iii) 
several duplicated or deleted genes from different CNVs and 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). The figure shows one of several top-scoring multigene network associated by the Ingenuity Pathway Analysis software to seventeen 
genes (gray shaded symbols) of the CS2_All data set which includes both duplicated and deleted genes. Several genes associated to the axon 
guidance signalling canonical pathway and to other nervous system functions and diseases map in this network (see also Supplementary Fig. 
2). A score of 29 (- log (p-value)) was obtained for this specific network calculated by the right-tailed Fisher's Exact Test. Functional Annotation of Genes Overlapping Copy Number Variants  Current Genomics, 2010, Vol. 11, No. 2    141 
patients may participate to the same pathogenic mechanism 
(e.g., a pathway). 
  Starting from the original list of CNVs’ genes (CS0) we 
have applied a two-step strategy to generate two new lists 
(CS1 and CS2) assumed to be strongly enriched in autism-
specific genes. In addition, the analyses were carried out 
separately for deleted or duplicated genes. This procedure 
was used with the aim of increasing the signal-to-noise ratio 
in functional annotation analyses. Here, by “signal” we mean 
the number of putative autism susceptibility genes overlap-
ping a CNV, and by “noise” all remaining genes in the same 
CNV or in CNVs that do not contain genes related to autism. 
It is worth noting here that the exclusion of deleted or dupli-
cated genes in patients that are also reported in Database of 
Genomic Variants (enrichment step 1) may have also caused 
the removal of some susceptibility genes for autism. Indeed, 
such susceptibility genes are expected to occur in the general 
population and therefore are likely to be reported in DGV 
database which contains only data originally described in 
healthy controls. For instance, we noted that a strong candi-
date gene for autism, NRXN1 [2, 4, 15, 16, 27], did not sur-
vive the first filtering procedure and was not used for func-
tional annotation analyses. Despite these considerations it is 
reasonable to expect that the number of susceptibility genes 
for autism would be higher in autistic patients than in non-
autistic individuals implying that the number of excluded 
genes after the first enrichment step (CS0>CS1) was proba-
bly very low. Moreover, as our results show (summarized 
below) the exclusion of the DGV genes revealed to be a 
critical and necessary step to increase the sensitivity of our 
functional annotation analyses. Support to this prediction is 
provided in our results by at least four observations: (i) no 
detection of statistically significant GO terms with CS0 lists, 
(ii) no detection of statistically significant GO terms with the 
list of excluded genes, (iii) detection of a significantly higher 
number of GO terms, functions and pathways obtained with 
CS2 gene lists compared to CS1 gene lists, (despite the large 
difference in genes’ number between the two lists, see Table 
2), (iv) nervous system related genes are largely overrepre-
sented in CS2 gene lists compared to CS1 gene lists (see 
Supplementary Tables 2,  3,  4). Specifically, many more 
nervous system related functions, pathways and GO terms 
were detected by CS2_Loss (deleted) compared to 
CS2_Gain (duplicated) gene lists. This result is consistent 
with the observation that most CNV mutations in persons 
with autism are deletions [1]. Furthermore, it may also be 
speculated that the putative pathogenic role of some genes of 
CS2_Loss list would consist in an unmasking of a recessive 
mutation (loss of heterozygosity) caused by a de novo CNV 
loss in some patients.  
  We noted that seven genes in CS2_Loss list have been 
tentatively or strongly linked to autism in previous studies 
many of which did not use CNV analysis. A first group in-
clude WNT2: [28]; SEMA5A: [29]; CADPS2: [29-31]; 
CTTNBP2: [32]. In addition, the arginine-vasopressin (AVP) 
gene (deleted in one patient from the [1], dataset) may be 
considered a candidate gene for autism because of its func-
tional partner. Indeed, the AVP gene encodes the ligand for 
the AVP receptor 1a (AVPR1a) and polymorphisms in this 
last gene have been shown to be in linkage and in linkage 
disequilibrium with autism [33]. Furthermore, two other de-
leted genes have also been previously reported in autistic 
patients, namely FOXP2 [34] and OXT [1]. It is worth men-
tioning here that FOXP2 protein dramatically down-
regulates CNTNAP2, a strong candidate gene for autism [35, 
36], whereas OXT gene encodes the neuropeptide binding 
the oxytocin receptor (OXTR), another strong candidate 
gene for autism [37-40].  
  Several studies have reported that in some autistic pa-
tients CNVs affect genes involved in synapse formation and 
function [2, 4, 41, 42]. In other studies that have used over-
representation analyses, genes overlapping CNVs detected in 
autistic patients have been annotated to a variety of func-
tional categories including those related to cell adhesion 
[15], ubiquitin pathway and neuronal cell-adhesion [16], 
glycobiology [43]; phosphatidylinositol signaling pathway 
[42]. It is interesting that these functional categories refer to 
very basic mechanisms that also play important roles in vari-
ous phases of neurodevelopment such as those we have iden-
tified in our functional annotation analysis, i.e., neurogene-
sis, neuron migration, axon pathfinding. This suggests that a 
multiplicity of molecular functions potentially affected by 
CNVs may underly the same altered cellular process. 
Moreover, this pathogenic model is consistent with the ge-
netic heterogeneity underlying autism because mutations in 
different genes from different patients would disrupt the 
same molecular pathway or cellular process [9]. In turn, a 
variety of molecular/cellular functions may also account for 
the phenotypic heterogeneity observed in autistic patients. 
Indeed, though the metapopulation of autistic patients we 
have investigated is homogeneous for autism diagnosis 
(same core symptoms), is expected to be heterogeneous for 
(i) different degree of severity of autistic core symptoms 
among patients, (ii) presence only in sub-groups of patients 
of peculiar clinical and sub-clinical phenotypes (beside the 
core symptoms). Inherently, patients from the four CNV 
studies [1-4] were not stratified according to specific endo-
phenotypes. 
  Our functional annotation analysis has also uncovered 
several other biofunctions and pathways unrelated to nervous 
system (see Supplementary Tables 2 and 3). For at least 
some of these functions e.g., those ones related to immune 
system and mitochondrion (just to mention few relevant ex-
amples), a strong link to autism has been proposed (e.g., [44, 
45]). Alternatively such non-CNS related functions may be 
due in theory to other reasons. First, within a CNV, CNS 
related genes may co-exist with non-CNS related genes and 
if these genes share common non-CNS related functions they 
may be detected by IPA and GO (a sort of hitchicking’s ef-
fect). Second, the same gene(s) may play multiple roles both 
CNS related and non-CNS related. Third, genes currently 
defined as non-CNS related may instead play a yet unknown 
role in CNS; these genes are currently classified in IPA and 
GO as non-CNS related terms, functions, pathways. Fourth, 
CNV in genes that are unrelated to autism are included in the 
analysis as an effect of the heterogeneity (phenotypic and 
genetic) of population, in that not all CNVs in the genome of 
an autistic patient are related to autism even after removal of 
DGV genes. If such CNVs are enriched in genes sharing a 
common function (unrelated to nervous system), such func-
tion will be detected by IPA and GO. For example, we noted 
that some GO terms or IPA biofunctions and pathways were 142    Current Genomics, 2010, Vol. 11, No. 2  Sbacchi et al. 
detected just because members of certain multigene families 
were clustered within a single CNV in a single patient. 
  The identification of 21 genes associated to “axonal 
guidance signalling” pathway raises the possibility that in a 
subgroup of patients (these 21 genes are overall deleted or 
duplicated in 23 patients) autism could be caused by a spe-
cific dysfunction in this early process of neurodevelopment. 
This number probably underestimates the fraction of patients 
having a genomic/genetic defect affecting axon pathfinding 
since genes/proteins not classified in this process may be 
involved too. Few examples in our results include proteins 
involved in mitochondrial function, cytoskeletal proteins 
among others. 
  Axon formation, growth and guidance is very important 
for establishing the correct pattern of neuronal connectivity 
during development. An altered pattern of connectivity (“de-
velopmental disconnection”) has been proposed as a major 
etiological mechanism for autism [46, 47]. Axon guidance 
signalling, in particular, regulates the progression of growth 
cone, a specialized structure sitting at the tip of migrating 
axons, guiding the axon until it reaches its final destination 
where it forms a synaptic connection with the right part-
ner(s). This is a highly regulated, multistep process involving 
many molecules acting as extracellular guidance cues, 
growth factors, plasma membrane-bound receptors, signal 
transducers, regulators of cytoskeleton organization, etc. 
[48]. Interestingly, the 21 proteins associated in our study to 
“axon guidance signalling” appear to function at different 
levels of distinct but partly overlapping signalling cascades 
in this pathway (see Supplementary Fig. 2).  
  Very recently published studies carried out on autistic 
patients have identified several genes (cited hereinafter) in-
volved in axon pathfinding. The value of these data is en-
hanced by the diversification of methods and approaches 
used: APC [49] association study, [50]; PI3 kinases [51] re-
view article, [42] CGH-microarray; Tsc1/2 [52]; SLIT1 [53] 
association study; ROBO3 and ROBO4 [54] association 
study; ROBO1 and ROBO2 [54] analysis of mRNA levels in 
lymphocytes; SEMA5A [29] analysis of mRNA levels in 
lymphoblastoid cell lines and [55] whole-genome association 
study; RUNX3 and SEMA4C [56] analysis of mRNA levels 
in peripheral blood cells; ADORA2A, GNAS, MARCKS, 
MYH10, SLIT2, EXT1, NFKB1, OMG, RHOA, DST, 
FNBP1 [12] analysis of mRNA levels in lymphoblastoid 
cells. Very recently, Glessner et al. [16] reported on the as-
sociation of some genes overlapping CNVs in autistic pa-
tients with “axonal guidance signalling” pathway. It is in-
triguing that with very few exceptions (SEMA5A and some 
members of the ROBO family) in each of these studies, in-
cluding our own, a different set of axon growth and guidance 
genes has been implicated. Thus our results and data from 
the literature provide overwhelming evidences in favour of 
axon pathfinding hypothesis proposed here, at the same time 
they well illustrate the recently proposed concept of 
“Autism: many genes, common pathways” [9]. 
  Imaging studies have revealed functional anatomy altera-
tions of distributed networks, as well as structural deficits of 
discrete white matter tracts in these patients [57-60]. These 
data, together with studies showing altered white matter 
maturation in autism [61] led to the development of the so-
called “underconnectivity theory” of autism, which points to 
the interaction of multiple partial cortico-cortical and cor-
tico-striatal disconnections as one of the main pathological 
processes of autism [58]. All these pathological and physio-
logical findings in autistic patients might be explained also 
assuming deficits in the axon pathfinding process, in turn 
leading to an altered pattern of connectivity. 
CONCLUDING REMARKS  
  GO and IPA analyses have provided several lines of evi-
dences that our two-step enrichment strategy has generated a 
set of genes (CS2 = 514 genes) many of which are probably 
related to nervous system development and function thus 
suggesting their relation to autism’s etiology. We have also 
investigated on the known expression of these genes in hu-
man tissues and found that many transcripts have been de-
tected in nervous system with a significant proportion of 
them expressed in brain regions that have been found altered 
in autistic patients (e.g., amygdala, cerebral cortex, cerebel-
lum, see Supplementary Table 4). The precise mechanism by 
which these genes would interfere with neurodevelopment 
thus predisposing to autism may be different from gene to 
gene. Genes/proteins do not have only one function, the 
same gene can express a number of proteins and even a sin-
gle protein can have multiple functions depending on the 
developmental stage, CNS area, protein levels, etc. Many 
genes annotated in our study to nervous system development 
and functions (see Supplementary Table 5) have multiple 
functions suggesting that a variety of pathogenic mecha-
nisms are implicated in autism.  
  The results of our study are also consistent with the hy-
pothesis that the “connectivity genes”, in autistic patients, 
may affect several early phases of neurodevelopment thus 
providing further support to the etiological theory of “devel-
opmental disconnection” of autism [46, 47]. In our study we 
have in particular highlighted the potential pathogenic role of 
axon pathfinding. We propose that the majority of genes 
associated to nervous system development and function in 
this study represent novel candidates susceptibility genes for 
autism deserving further investigation. 
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